Home
/
IRONWOOD PHARMACEUTICALS INC
/
Financials
/
Quarterly
IRONWOOD PHARMACEUTICALS INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that IRONWOOD PHARMACEUTICALS INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$69.16M
May 4, 2018
Q3
2017
Sep 30, 2017
$86.83M
Nov 2, 2017
Q2
2017
Jun 30, 2017
$65.08M
Aug 3, 2017
Q1
2018
Mar 31, 2017
$52.17M
May 4, 2018
Q3
2017
Sep 30, 2016
$66.11M
Nov 2, 2017
Q2
2017
Jun 30, 2016
$54.35M
Aug 3, 2017
Q1
2017
Mar 31, 2016
$66.04M
May 8, 2017
Q3
2016
Sep 30, 2015
$39.57M
Nov 7, 2016
Q2
2016
Jun 30, 2015
$27.74M
Aug 8, 2016
Q1
2016
Mar 31, 2015
$28.93M
May 10, 2016
Q3
2015
Sep 30, 2014
$16.92M
Nov 5, 2015
Q2
2015
Jun 30, 2014
$6.84M
Aug 7, 2015
Q1
2015
Mar 31, 2014
$14.61M
May 6, 2015
Q3
2014
Sep 30, 2013
$4.93M
Nov 5, 2014
Q2
2014
Jun 30, 2013
$9.66M
Aug 5, 2014
Q1
2014
Mar 31, 2013
$3.26M
Apr 29, 2014
Q3
2013
Sep 30, 2012
$96.41M
Oct 28, 2013
Q2
2013
Jun 30, 2012
$14.60M
Aug 8, 2013
Q1
2013
Mar 31, 2012
$12.25M
Apr 23, 2013
Q3
2012
Sep 30, 2011
$12.22M
Nov 6, 2012
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$122.06M
Nov 10, 2025
Q2
2025
Jun 30, 2025
$85.24M
Aug 11, 2025
Q1
2025
Mar 31, 2025
$41.14M
May 12, 2025
Q3
2025
Sep 30, 2024
$91.59M
Nov 10, 2025
Q2
2025
Jun 30, 2024
$94.40M
Aug 11, 2025
Q1
2025
Mar 31, 2024
$74.88M
May 12, 2025
Q3
2024
Sep 30, 2023
$113.74M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$107.38M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$104.06M
May 9, 2024
Q3
2023
Sep 30, 2022
$108.64M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$97.23M
Aug 9, 2023
Q1
2022
Jun 30, 2022
$97.23M
Aug 4, 2022
Q1
2023
Mar 31, 2022
$97.53M
May 4, 2023
Q3
2022
Sep 30, 2021
$103.75M
Nov 3, 2022
Q2
2021
Jun 30, 2021
$104.03M
Aug 5, 2021
Q1
2022
Jun 30, 2021
$104.03M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$88.85M
May 5, 2022
Q3
2021
Sep 30, 2020
$103.47M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$89.43M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$79.94M
May 6, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$40.08M
Nov 10, 2025
Q2
2025
Jun 30, 2025
$23.60M
Aug 11, 2025
Q1
2025
Mar 31, 2025
($37.39M)
May 12, 2025
Q3
2025
Sep 30, 2024
$3.65M
Nov 10, 2025
Q2
2025
Jun 30, 2024
($860.0K)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($4.16M)
May 12, 2025
Q3
2024
Sep 30, 2023
$15.32M
Nov 7, 2024
Q2
2024
Jun 30, 2023
($1.06B)
Aug 8, 2024
Q1
2024
Mar 31, 2023
$45.71M
May 9, 2024
Q3
2023
Sep 30, 2022
$50.32M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$37.08M
Aug 9, 2023
Q3
2022
Jun 30, 2022
$37.08M
Nov 3, 2022
Q1
2022
Jun 30, 2022
$37.08M
Aug 4, 2022
Q1
2023
Mar 31, 2022
$38.80M
May 4, 2023
Q3
2022
Mar 31, 2022
$38.80M
Nov 3, 2022
Q3
2022
Sep 30, 2021
$55.85M
Nov 3, 2022
Q2
2021
Jun 30, 2021
$391.30M
Aug 5, 2021
Q3
2022
Jun 30, 2021
$391.30M
Nov 3, 2022
Q1
2022
Jun 30, 2021
$391.30M
Aug 4, 2022
Q2
2021
Mar 31, 2021
$39.93M
Aug 5, 2021
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$75.48M
Nov 10, 2025
Q2
2025
Jun 30, 2025
$45.32M
Aug 11, 2025
Q1
2025
Mar 31, 2025
($29.11M)
May 12, 2025
Q3
2025
Sep 30, 2024
$25.64M
Nov 10, 2025
Q2
2025
Jun 30, 2024
$24.98M
Aug 11, 2025
Q1
2025
Mar 31, 2024
$11.02M
May 12, 2025
Q3
2024
Sep 30, 2023
$40.02M
Nov 7, 2024
Q2
2024
Jun 30, 2023
($1.08B)
Aug 8, 2024
Q1
2024
Mar 31, 2023
$60.10M
May 9, 2024
Q3
2023
Sep 30, 2022
$68.47M
Nov 9, 2023
Q1
2022
Jun 30, 2022
$55.66M
Aug 4, 2022
Q2
2023
Jun 30, 2022
$55.66M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$57.85M
May 4, 2023
Q3
2022
Sep 30, 2021
$65.17M
Nov 3, 2022
Q1
2022
Jun 30, 2021
$65.10M
Aug 4, 2022
Q2
2021
Jun 30, 2021
$65.10M
Aug 5, 2021
Q1
2022
Mar 31, 2021
$45.40M
May 5, 2022
Q3
2021
Sep 30, 2020
$45.62M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$32.71M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$13.23M
May 6, 2021